Back to search

Article

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)

2025-12-04

Abstract excerpt

<title>Abstract</title> <p>Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent a paradigm shift in precision oncology, exploiting synthetic lethality to selectively target tumor cells deficient in homologous recombination repair (HRR) pathways, particularly those harboring BRCA1/2 mutations (Lord & Ashworth, 2017). PARP enzymes, primarily PARP1 and PARP2, are central to the repair of single-strand DNA...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c0679d8c-60d2-59a0-98e2-4c216cdb9c8f
DOI
10.21203/rs.3.rs-8175121/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)DOI 10.21203/rs.3.rs-8175121/v1
Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity
Molecular Pathways: Targeting PARP in Cancer TreatmentSemantic proximity
PARPi, BRCA, and gaps: controversies and future researchSemantic proximity
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) InhibitorsSemantic proximity
Evolving DNA repair synthetic lethality targets in cancerSemantic proximity
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity
Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicSemantic proximity
PARP inhibitors: Synthetic lethality in the clinicSemantic proximity
Current status of poly(ADP-ribose) polymerase inhibitors and future directionsSemantic proximity
Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity
The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity
Select a neighboring publication to make it the new centre.